Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates

9 Sept 2021

Abstract excerpt

Huntington's disease (HD) is caused by a CAG trinucleotide repeat expansion in the first exon of the huntingtin (HTT) gene coding for the huntingtin (HTT) protein. The misfolding and consequential aggregation of CAG-expanded mutant HTT (mHTT) underpin HD pathology. Our interest in the life cycle of HTT led us to consider the development of high-affinity small-molecule binders of HTT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34504195
DOI: 10.1038/s41598-021-97334-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesPMID 34504195Read ↗

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.Semantic proximity Read ↗

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s diseaseSemantic proximity Read ↗

PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non-For-Profit Scientific Management.Semantic proximity Read ↗

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s diseaseSemantic proximity Read ↗

Preclinical evaluation of [11C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read ↗

Preclinical evaluation of [ <sup>11</sup> C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read ↗

PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.Semantic proximity Read ↗

In Vivo PET Imaging of [18F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease.Semantic proximity Read ↗

In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington DiseaseSemantic proximity Read ↗

Longitudinal Preclinical Evaluation of the Novel Radioligand [11C]CHDI-626 for PET Imaging of Mutant Huntingtin Aggregates in Huntington’s DiseaseSemantic proximity Read ↗

Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.Semantic proximity Read ↗

Preclinical evaluation of the novel [ <sup>18</sup> F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.